Cerebrolysin Dosing Protocol: 60 mg Vial & Trial Doses
Cerebrolysin (porcine brain peptide mixture): the IV doses used in clinical trials, the community-reported subcutaneous schedule for the 60 mg research vial (often sold as CBL60), reconstitution math, and what the evidence shows.
Quickstart highlights
Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids made by controlled digestion of pig brain proteins.
- Two different products: the licensed ampoule solution used in trials (dosed in mL, IV, in hospital) and the 60 mg lyophilized research vial, often sold as CBL60 (no trial data).
- Trial doses: 30 mL daily IV for 10–21 days in stroke; 20 mL daily in vascular dementia; 50 mL daily, then 10 mL courses, in brain injury; 10–60 mL in Alzheimer's.
- Research vial math: 60 mg + 6 mL bac water = 10 mg/mL, so 60 mg = 6 mL.
- The subcutaneous 60 mg once- or twice-weekly schedule is community-reported; no trial used subcutaneous injection.
- Cochrane (2023) found no reduction in deaths after stroke. See the Cerebrolysin peptide page for the evidence.
Dosing table
For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.
| Week | Dose (µg) | Units | Frequency | Notes |
|---|---|---|---|---|
| 1 | — | — | IV infusion daily x 10 days | From clinical trials, not community-reported: 20 mL of the licensed ampoule solution by IV infusion once daily was used in a 242-patient vascular dementia trial (PMID 20656516); stroke trials used 30 mL daily for 10–21 days. Given in hospital under medical supervision. This row is in mL of the licensed solution and does not apply to the 60 mg research vial. |
| 2-12 | — | — | Subcutaneous 60 mg 1–2x weekly | Community-reported, not from a trial: 60 mg of the research vial subcutaneously, quoted as once or twice weekly; at 10 mg/mL that is 6 mL per dose. No trial used subcutaneous injection or the lyophilized vial, and there is no published conversion between 60 mg of powder and the mL trial doses. |
Your free Cerebrolysin tracker
- Dose reminders
- Injection logging
- Cycle progress
Reconstitution steps
- Add 6 mL bacteriostatic water to the 60 mg lyophilized vial, running it slowly down the vial wall.
- Swirl gently until dissolved; do not shake.
- Final concentration: 10 mg/mL. At 10 mg/mL, 60 mg = 6 mL.
- This math applies only to the research powder. Trial doses were mL of the licensed ampoule solution given by IV infusion in hospital, and they do not convert to this vial.
- Label with the date; refrigerate at 2–8 °C and use within 28 days.
Supplies needed
See your prescribing clinician for a supplies list.
Protocol overview & cycle notes
Reference schedule and reconstitution math for a 60 mg Cerebrolysin research vial, set alongside the IV doses used in clinical trials. Trial doses are mL of the licensed ampoule solution given in hospital and do not convert to the research vial; the subcutaneous schedule is community-reported, not from a trial.
Off-cycle: Not established for the research vial. Trials gave single courses of 10–21 days; the traumatic brain injury trials added two 10-day courses of 10 mL daily after the first course, and the vascular dementia trial gave two treatment cycles. No study has tested breaks between courses.
Storage & handling
Injection & tracking tips
- In trials, Cerebrolysin was given by IV infusion in hospital. IV infusion is not a home procedure.
- No trial used subcutaneous injection. A 60 mg dose at 10 mg/mL is 6 mL, a large volume for one subcutaneous site; community protocols split it across 2–3 sites of about 2 mL.
- Rotate injection sites and use a new sterile syringe every time.
- No study has tested Cerebrolysin combined with Semax, BPC-157 or other nootropics, so combination protocols are untested.
Tracking
Logging helps you and your provider spot patterns and adjust dose or timing.
- If used for a diagnosed condition, ask your clinician to record a cognitive score (for example MoCA) at baseline and after each course.
- For stroke or dementia, track activities of daily living with your care team.
- Record any reaction during or after each injection or infusion and report it to the supervising clinician.
How this works & references
Sources
- Ziganshina LE, Abakumova T, Nurkhametova D, et al. "Cerebrolysin for acute ischaemic stroke." Cochrane Database Syst Rev. 2023;10(10):CD007026. PMID: 37818733
- Heiss WD, Brainin M, Bornstein NM, et al. "Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial." Stroke. 2012;43(3):630-6. PMID: 22282884
- Muresanu DF, Heiss WD, Hoemberg V, et al. "Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial." Stroke. 2016;47(1):151-9. PMID: 26564102
- Guekht AB, Moessler H, Novak PH, et al. "Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial." J Stroke Cerebrovasc Dis. 2011;20(4):310-8. PMID: 20656516
- Muresanu DF, Florian S, Hömberg V, et al. "Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial." Neurol Sci. 2020;41(5):1171-1181. PMID: 31897941
- Alvarez XA, Cacabelos R, Laredo M, et al. "A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease." Eur J Neurol. 2006;13(1):43-54. PMID: 16420392
- Cui S, Chen N, Yang M, et al. "Cerebrolysin for vascular dementia." Cochrane Database Syst Rev. 2019;2019(11). PMID: 31710397
- Gevaert B, D'Hondt M, Bracke N, et al. "Peptide profiling of Internet-obtained Cerebrolysin using high performance liquid chromatography - electrospray ionization ion trap and ultra high performance liquid chromatography - ion mobility - quadrupole time of flight mass spectrometry." Drug Test Anal. 2015;7(9):835-42. PMID: 26017115
Frequently asked questions
What is the Cerebrolysin 60 mg dosage?
What is CBL60?
What dose of Cerebrolysin was used in clinical trials?
Can Cerebrolysin be injected subcutaneously?
How do you reconstitute a 60 mg Cerebrolysin vial?
How is Cerebrolysin given IV?
Is Cerebrolysin FDA-approved?
Related protocols
KLOW Blend Dosing Protocol — BPC-157, TB-500, KPV & GHK-Cu Guide
KLOW peptide blend (BPC-157 + TB-500 + KPV + GHK-Cu) dosing guide for tissue repair, anti-inflammatory support, and extracellular matrix remodeling — the GLOW blend plus KPV.
View protocolGLOW Blend Dosing Protocol — BPC-157, TB-500 & GHK-Cu Skin & Repair Guide
GLOW peptide blend (BPC-157 + TB-500 + GHK-Cu) dosing guide for tissue repair, angiogenesis, and collagen and connective-tissue remodeling.
View protocolVilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide
Vilon (Lys-Glu dipeptide) bioregulator: community-reported dosing, reconstitution math for the 20 mg vial, and what the research does and doesn't support.
View protocolVesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide
Vesugen (Lys-Glu-Asp tripeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.
View protocolThis content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.
